From the Department of Allergy and Clinical
Immunology, National Jewish Center for Immunology and Respiratory
Medicine, Denver, Colorado 80206, the ** Research Service, Veterans
Affairs Medical Center, Denver, Colorado 80220, the
§ Departments of Biochemistry and Molecular Genetics and
Medicine, University of Colorado Health
Sciences Center, Denver, Colorado 80220, and the
Department of
Biochemistry, University of Saskatchewan,
Saskatoon, Saskatchewan, Canada S7N-5E5
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Earlier studies from our laboratory demonstrated an insulin-mediated increase in cAMP-response element binding protein (CREB) phosphorylation. In this report, we show that insulin stimulates both CREB phosphorylation and transcriptional activation in HepG2 and 3T3-L1 cell lines, models of insulin-sensitive tissues. Insulin stimulated the phosphorylation of CREB at serine 133, the protein kinase A site, and mutation of serine 133 to alanine blocked the insulin effect.
Many of the signaling pathways known to be activated by insulin have been implicated in CREB phosphorylation and activation. The ability of insulin to induce CREB phosphorylation and activity was efficiently blocked by PD98059, a potent inhibitor of mitogen-activated protein kinase kinase (MEK1), but not significantly by rapamycin or wortmannin. Likewise, expression of dominant negative forms of Ras or Raf-1 completely blocked insulin-stimulated CREB transcriptional activity. Finally, we demonstrate an essential role for CREB in insulin activation of fatty-acid synthase and fatty acid binding protein (FABP) indicating the potential physiologic relevance of insulin regulation of CREB.
In summary, insulin regulates CREB transcriptional activity in
insulin-sensitive tissues via the Raf MEK pathway and has an impact
on physiologically relevant genes in these cells.
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Insulin binding to its cell surface receptor results in alterations in the expression of many genes for cellular growth, differentiation, and proliferation. Specific insulin responsive elements have been identified in the promoters of several genes (1-4). Peroxisome proliferator-activated receptors and other steroid hormone receptors have been implicated in regulating gene transcription through these insulin responsive elements (2, 4, 5). In other genes, insulin responsive sites have been mapped to regions containing cAMP responsive elements (CREs)1 and serum responsive elements (6-9). Consistent with these findings, many insulin-regulated genes are also regulated by extracellular stimuli that modulate intracellular cAMP levels (2, 10-17) (Table I). Previously, we demonstrated that phosphorylation of CREB was stimulated by insulin in primary rat adipocytes and HIRc cells (18, 19). This observation posed an important question regarding the impact of insulin-mediated CREB phosphorylation on CREB transactivation and the post-receptor pathways activated by insulin responsible for this effect.
|
Cyclic AMP regulates the transcription of target genes primarily through the phosphorylation of the cAMP-response element binding protein (CREB) by protein kinase A (PKA) on serine 133 (of CREB-341 or serine 119 of CREB-327) of the CREB molecule (20-23). We demonstrated an analogous response to insulin and identified that this increase in phosphorylation was at least in part due to a decrease in nuclear protein phosphatase-2A activity. These experiments were the first to show a transient increase in CREB phosphorylation and regulation of a nuclear, serine/threonine-specific protein phosphatase in response to activation of a tyrosine kinase growth factor receptor. Simultaneously, Ginty et al. (24) described a similar increase in CREB phosphorylation in response to nerve growth factor (NGF), which binds to another tyrosine kinase growth factor receptor, in PC12 cells. It was stated in this paper that CREB phosphorylation alone by NGF was not sufficient to activate a Gal-4 CREB reporter. Since the time of these initial observations, an explosion of new data on growth factor, Ca2+, and cytokine regulation of CREB has emerged, and a number of post-receptor signaling pathways including ERK 1/2 pathway, pp70 S6 kinase pathway, p38 pathway, and PI-3 kinase pathway have been implicated in CREB regulation. The kinases responsible for serine 133 phosphorylation of CREB in addition to PKA have been in the rsk or MAP KAP kinase family, specifically RSK2, MAP KAP2, MAP KAP3, and MNK.
In this report, we demonstrate that insulin stimulates the phosphorylation of CREB at serine 133 and thereby enhances CREB transcriptional activity in the HepG2, human hepatoma cells, and in mouse 3T3-L1 fibroblasts and adipocytes. CREB phosphorylation and activation increased rapidly following the addition of physiological concentrations of insulin, but no change in CREB DNA binding activity was observed. Pharmacological inhibitors of PI-3 kinase or pp70 S6 kinase did not significantly inhibit insulin-stimulated CREB phosphorylation and activity. However, inhibition of the MAP kinase signaling pathway through the expression of a dominant negative Ras and Raf-1, or with the MAP kinase kinase (MEK) inhibitor, PD98059, blocked the effects of insulin on CREB. These studies indicate that the phosphorylation of CREB at serine 133 in response to insulin requires the MAP kinase pathway. Furthermore, we demonstrate that dominant negative CREB, K-CREB, will disrupt insulin activation of transcription from the promoters of the phosphoenolpyruvate carboxykinase (PEPCK), fatty-acid synthetase (FAS), and fatty acid binding protein (FABP) genes indicating a plausible physiologic role for CREB in adipocyte function.
![]() |
EXPERIMENTAL PROCEDURES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Materials-- Cell culture media and supplies were from Life Technologies, Inc. (Beverly, MA), Gemini Bioproducts (Gaithersburg, MD), and Specialty Media, Inc. (Lavallette, NJ). 3T3-L1 fibroblasts were provided by Dr. Ted Ciraldi (La Jolla, CA). Luciferase assay reagents were obtained from Analytical Luminescence Laboratory (San Diego, CA), and chloramphenicol acetyltransferase enzyme-linked immunosorbent assay kits were from Boehringer Mannheim. A plasmid containing an enhancerless thymidine kinase (TK) promoter linked to four copies of the Gal4 regulatory sequence driving expression of a luciferase reporter gene (pGal4TK-LUC) was provided by Dr. James Hoeffler (Invitrogen, San Diego, CA). Expression vectors for Gal4-CREB proteins with serine to alanine substitutions at amino acids 117, 129, and 133 in the CREB transactivation region linked to the Gal4 DNA binding domain (designated Gal4-CREB-341 S117A, S129A, and S133A, respectively) were generated as described elsewhere (25). An expression vector (pRSV-KCREB) for the dominant negative CREB inhibitor protein, KCREB, was provided by Dr. Richard Goodman (Oregon Health Sciences University, Portland, OR). Plasmids for the expression of constitutively active Ras (pSVRas), dominant negative Raf (pRSVC4BRaf) were supplied by Dr. Ulf Rapp (Strathlenkunde, Germany). [32P]orthophosphate was purchased from ICN (Irvine, CA). Okadaic acid was obtained from Upstate Biotechnology, Inc. (Lake Placid, NY). CREB- and P-CREB-specific antibodies were purchased from New England Biolabs (Beverly, MA). All other reagents were of molecular biology grade or better and were purchased from Sigma. Rapamycin and wortmannin were obtained from BioMol (Plymouth Meeting, PA), and PD98059 was a gift from Parke-Davis.
Cell Lines and Transfection Procedures-- HepG2, human hepatoma cells, were obtained from the American Type Culture Collection (Rockville, MD) and grown in low glucose Dulbecco's modified Eagle's medium (DMEM)/F12 containing 5% fetal calf serum (FCS), and 5% calf serum. 3T3-L1 fibroblasts were a gift of Ted Ceraldi (University of California, San Diego). 3T3-L1 fibroblasts were passaged in low glucose DMEM plus 10% FCS, 50 µg/ml gentamicin, 1 mM L-glutamine, and 450 ng/ml fungizone. 3T3-L1 fibroblasts were differentiated into adipocytes after reaching confluency by the addition of differentiation medium (high glucose DMEM containing 10% FCS, 50 µg/ml gentamicin, 1 mM L-glutamine, 500 µM isobutylmethylxanthine, 1 µM dexamethasone, and 1 µg/ml insulin). After 2 days, the 3T3-L1 cells were transferred to adipocyte growth medium (high glucose DMEM plus 10% FCS, 50 µg/ml gentamicin, 1 mM L-glutamine, and 1 µg/ml insulin) and refed every 2 days (26). Differentiation of fibroblasts to mature adipocytes was confirmed by Oil Red staining of lipid vesicles.
Plates of HepG2 and 3T3-L1 fibroblasts and adipocytes were grown to 70-80% confluency and transfected with the indicated plasmids by calcium phosphate-DNA coprecipitation as described by Wadzinski et al. (27) or using LipofectAMINE according to the manufacturer's directions (Life Technologies, Inc.). Cells were treated with insulin and/or other reagents at the concentrations and times specified in the figure legends. Luciferase assays were performed on a Monolight 2010 luminometer using the Enhanced Luciferase Assay kit (Analytical Luminescence Laboratory, San Diego, CA) according to the supplier's directions. Transfection efficiencies were normalized by cotransfecting the cells with a plasmid containing a chimeric SV40 promoter/Immunoprecipitation and Tryptic Phosphopeptide Mapping of 32P-CREB-- HepG2 and 3T3-L1 fibroblasts and adipocytes were grown to approximately 80% confluency as described above. Plates of cells (2.5 × 106/plate) were washed with phosphate-buffered saline, and the medium was replaced with 5 ml of phosphate-free DMEM containing 1% bovine serum albumin and 1 mCi of [32P]orthophosphate. The plates were incubated 4-16 h at 37 °C and then treated with insulin and/or other agents for the indicated times.
At each time point, the medium was removed from the cells, which were washed once with cold phosphate-buffered saline. The cell pellets were lysed in 1 ml of 20 mM Hepes, pH 7.9, containing 1% sodium dodecyl sulfate (SDS), and 0.1% 2-mercaptoethanol in a boiling water bath for 2 min. The lysates were diluted with 9 ml of 20 mM Hepes, pH 7.9, containing 1% Nonidet P-40, 1 mM EDTA, 1 µg/ml leupeptin, 1 mM benzamidine, 1 µg/ml pepstatin A, 50 mMWestern Blot Analysis of CREB and P-CREB-- Lysates from HepG2 cells and 3T3-L1 fibroblasts and adipocytes treated with insulin and/or other reagents were prepared as described above at the times indicated in the figure legends. After correcting for protein concentrations, the lysates were resolved on 10% polyacrylamide-SDS gels and transferred to nitrocellulose. The nitrocellulose blots were blocked with phosphate-buffered saline containing 5% dry milk and 0.1% Tween 20 and then treated with antibodies that recognize phosphorylated CREB (P-CREB) alone or that recognize both unphosphorylated and phosphorylated forms of CREB. The blots were washed and subsequently treated with goat anti-rabbit IgG conjugated to alkaline phosphatase. After the blots were washed, specific immune complexes were visualized with bromochloroindoyl phosphate and nitro blue tetrazolium.
In some experiments, proteins were transferred to PVDF membranes that were then blocked in 20 mM Tris-HCl, pH 7.9, 8.5% NaCl (TBS) containing 5% Blotting Grade Non-Fat Dry Milk and 0.1% Tween 20 for 1 h (Blocking Buffer). The blots were then incubated with the indicated primary antibodies in TBS containing 5% bovine serum albumin and 0.1% Tween 20. Membranes were then rinsed three times in Blocking Buffer and then twice in 10 mM Tris-HCl, pH 9.5, 10 mM NaCl, 1 mM MgCl2. Blots were then incubated with 1:500 dilution of CDP-Star reagent prepared in 1 × Assay Buffer (both reagents from New England Biolabs, Beverly, MA) for 5 min and then exposed to film.Electrophoretic Mobility Shift Assay-- The binding affinities of unphosphorylated CREB and CREB phosphorylated in response to insulin were calculated from equilibrium binding data obtained from electrophoretic mobility shift assays performed with concentrations of 32P-labeled CREB probe from 0.1 to 20 ng per 20-µl reaction. The binding of CREB to 32P-labeled probe was saturable at high probe concentrations and was found to be reversible since the addition of unlabeled CRE probe to electrophoretic mobility shift assay reactions prior to electrophoresis decreased CREB DNA binding as compared with reactions with no unlabeled probe. Nuclear extract preparations, electrophoretic mobility shift assays, and Scatchard analysis of equilibrium binding data were performed as described previously (29, 30).
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Insulin Stimulates Phosphorylation of CREB at Serine 133-- A number of laboratories have reported that the activation of certain tyrosine kinase/growth factor receptors, such as NGF receptor, epidermal growth factor receptor (24), and fibroblast growth factor receptor (4), increases the phosphorylation and transcriptional activity of the nuclear protein, CREB. In one of the first reports of this phenomenon, we demonstrated that insulin produced a transient increase in CREB phosphorylation in primary rat adipocytes (18). Our initial experiments also showed that insulin transiently decreased nuclear protein phosphatase 2A activity that could partly account for increased CREB phosphorylation (18, 19). However, the effect of insulin on CREB transcriptional activity was not addressed nor was the site(s) at which CREB was phosphorylated in response to insulin identified.
Insulin Stimulates CREB Phosphorylation at Serine 133 in a Time- and Dose-dependent Manner-- To assess further the impact of insulin on CREB phosphorylation, we used two cell lines representative of normal insulin-responsive tissues: HepG2 hepatoma cells derived from human liver and 3T3-L1 fibroblasts and adipocytes as representative of adipose tissue. As shown in Fig. 1A, both insulin and Bt2cAMP rapidly increased the level of 32P-labeled CREB in HepG2 cells (panel CREB IP). A significant increase in 32P-labeled CREB was noted after incubating the cells with insulin for only 20 min, and the levels continued to increase for at least 2 h. When the cells were treated with Bt2cAMP, maximal levels of CREB phosphorylation were observed after only 40 min. Similar results were obtained by Western blot analysis of nuclear extracts with antibodies that specifically recognize CREB phosphorylated at serine 133 (31) or (Fig. 1A, panel P-CREB Ab). These results indicated that at least one of the sites in the CREB protein molecule phosphorylated in response to insulin was the PKA recognition site. Total CREB protein levels did not change with either insulin or Bt2cAMP treatment as determined from Western blots using antibodies that recognize both unphosphorylated and phosphorylated forms of CREB (Fig. 1A, panel CREB Ab).
|
Insulin Stimulates CREB Transcriptional Activity-- Phosphorylation of CREB at serine 133 increases the transcriptional transactivation activity of the protein. To assess the ability of insulin to enhance CREB transcriptional activity, we measured the ability of insulin to regulate a luciferase reporter gene linked to the herpes simplex virus-thymidine kinase promoter containing four copies of the Gal4 response element (pGal4TK-LUC) in HepG2 cells and 3T3-L1 fibroblasts and adipocytes. The cells were cotransfected with an expression vector from which a chimeric protein containing the Gal4 DNA binding domain linked to the CREB transactivation region was expressed (pRSV-Gal4). Since mammalian cells lack transcription factors that bind the Gal4 consensus sequence, this system directly measures the effect of insulin on the CREB transactivation region of the chimeric protein. Control cells did not receive the Gal4-CREB expression plasmid. Transcription from the Gal4-responsive promoter was unaffected by insulin treatment in HepG2 cells in the absence of Gal4-CREB protein (Fig. 2A). However, when cotransfected with the Gal4-CREB-341 expression vector, insulin stimulated transcription from the Gal4 responsive promoter by 4.5-fold ± 0.27. Likewise, insulin stimulated Gal4-CREB responsive transcription 8.5-fold in 3T3-L1 fibroblasts and 4.45-fold in adipocytes.
|
Parameters of Insulin-stimulated CREB Transactivation--
The
ability of insulin to stimulate CREB transcriptional activity was
further characterized in both HepG2 and 3T3-L1 fibroblasts using the
Gal4-CREB system. Fig. 3 shows results
obtained with HepG2 cells alone as similar results were observed in
3T3-L1 cells (not shown). When HepG2 cells were treated with 10 nM insulin, Gal4-CREB-mediated transcription increased
linearly from 0 to 4 h of treatment (Fig. 3A).
Transcription levels remained elevated for at least 8 h and then
began to decline to basal levels (not shown). The time course for
transcription did not match the time course for CREB phosphorylation
shown in Fig. 1. However, similar differences have been reported for
the time courses of transcription (luciferase expression) and CREB
phosphorylation in response to cAMP analogs and appear to be due to the
lag in overall luciferase expression as compared with the more rapid
response of transcription alone. Gal4-CREB responsive transcription was
also dependent on the concentration of insulin used to treat the cells
(Fig. 3B). Transcription levels increased with insulin
concentrations from 1011 to 10
9
M. Concentrations of insulin higher than 10
9
M did not produce higher levels of transcription. Thus, the
ability of insulin to enhance CREB transactivation occurs rapidly and at physiological concentrations of insulin.
|
Insulin Stimulates CREB Transcriptional Activity through the Phosphorylation of Serine 133-- Our initial results demonstrated that insulin stimulated the phosphorylation of serine 133 of CREB. To confirm further the importance of serine 133 phosphorylation for CREB transcriptional activity, we next analyzed the ability of insulin to stimulate transcription from the Gal4-responsive promoter in the presence of wild type Gal4-CREB or Gal4-CREB proteins containing various mutations in the CREB transactivation domain (25). The wild type and mutant Gal4-CREB proteins were expressed at equivalent levels in these experiments as determined by Western blot analysis of cell lysates with Gal4-specific antibodies (data not shown). The data in Fig. 4 show that mutation of serine 133 to alanine completely blocks the ability of insulin to stimulate Gal4-CREB transcriptional activity in both HepG2 cells and 3T3-L1 fibroblasts. However, insulin was able to stimulate the transcriptional activity of other Gal4-CREB proteins having adjacent serines mutated to alanines (Gal4-CREBs S117A and S129A). Levels of basal transcription with these proteins was typically lower than observed with the wild type Gal4-CREB protein.
|
Effect of Pharmacologic Inhibitors on CREB Phosphorylation and Activity-- Recent data indicate that multiple signal transduction pathways are capable of regulating CREB serine 133 phosphorylation (24, 33-39). Insulin-regulated pathways that have been implicated for serine 133 phosphorylation by other growth factors, cytokines, and cytosolic calcium include MAP kinases, pp70 S6 kinase (which requires PI-3 kinase for insulin regulation), and PKC. We examined the contribution of these pathways to the regulation of CREB phosphorylation and activity in 3T3-L1 fibroblasts using various pharmacological inhibitors. As shown in Fig. 5A, the insulin-induced phosphorylation of CREB serine 133 was unaffected by pretreatment with rapamycin, an inhibitor of pp70 S6 kinase, and minimally, but not significantly, affected by wortmannin, an inhibitor of PI-3 kinase. Preliminary experiments with the PKC inhibitor, bisindolylmaleimide, have also showed no change in insulin-stimulated CREB phosphorylation (not shown). However, PD98059, a potent and specific inhibitor of MAP kinase kinase 1 (MEK 1), completely blocked the insulin-mediated increase in CREB phosphorylation. No change in total CREB content was observed with any of the inhibitors (not shown).
|
Effect of Constitutively Active and Dominant Negative Ras and Raf on Insulin-stimulated CREB Transcriptional Activity-- To confirm the previous observations implicating the MAP kinase pathway in insulin-stimulated CREB regulation, we measured the effect of insulin on transcription from the Gal4-responsive promoter in the presence of Gal4-CREB in 3T3-L1 fibroblasts cotransfected with plasmids for the expression of constitutively active Ras or Raf-1 (pSVRas and pRSVBXBRaf, respectively) or dominant negative Ras or Raf-1 (pZCRN17Ras and pRSVC4BRaf, respectively). In these experiments, insulin stimulated CREB-dependent transcription in control cells by 4.1 (Fig. 6). The expression of either constitutively active Ras or Raf significantly increased basal levels of transcription from the Gal-4-responsive promoter, but no additional stimulation with insulin was observed. The dominant negative forms of Ras and Raf did not affect basal levels of transcription but efficiently blocked the ability of insulin to stimulate CREB transcriptional activity. The inability of insulin to stimulate further CREB activity in cells expressing constitutively active Ras or Raf proteins and the ability of negative Ras and Raf to inhibit insulin-stimulated CREB activity support the contribution of the Ras-Raf-MEK1-MAP kinase pathway to insulin regulation of CREB transcriptional activity.
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Insulin is primarily a metabolic hormone that also regulates the proliferation and differentiation of a number of cells and tissues. One of the mechanisms by which insulin regulates transcription is through the phosphorylation and transcriptional activation of CREB in Rat-1A cells, hepatoma cells, preadipocyte, and adipocyte cell lines. Since our initial observations that insulin enhanced CREB phosphorylation in primary adipocytes and HIRc cell lines (18, 19), a number of groups have seen a similar response to other growth factors including NGF and fibroblast growth factor, via the ERK1/2 and p38 MAPK pathways (4, 24, 39). For these growth factors, both studied in neuronal cell lines, Rsk2 and MAPKAP2, rsk family kinases have been implicated in CREB regulation (4, 39). Additionally, PKC, elevated intracellular Ca2+, and IgG (via pp70 S6 kinase) can phosphorylate CREB on serine 133. Whether these phosphorylations lead to CREB transactivation appears to depend on cell type and whether the cells are exposed to other factors, such as cAMP agonists simultaneously (40). The importance of the work presented in this paper is the observation that in cell line models of classic, insulin-sensitive tissues, hepatocytes and adipocytes, insulin regulates this ubiquitous transcription factor that has been demonstrated to have a pivotal role in cellular differentiation (24, 40, 41).2
We initially observed that insulin led to CREB phosphorylation in primary adipocytes. This was an unexpected finding since insulin's actions classically oppose cAMP which, at that time, was felt to be the primary regulating agent for CREB (21-23, 31). Subsequently, we demonstrated that this enhanced CREB phosphorylation occurred in Rat-1A fibroblasts overexpressing normal human insulin receptors (HIRc cells) (18). The relevance of these observations to CREB transcriptional activity was assessed using multiple promoter constructs including the somatostatin CRE reporter and a truncated PEPCK CRE reporter, each of which would be regulated by endogenous CREB and other CRE binding transcription factors. Also, to assess CREB specifically and exclude other CRE binding transcription factors, the Gal4TKLUC reporter system, a Gal4-CREB responsive transcription system was employed. In this system, either insulin or Bt2cAMP stimulated transcription to a similar extent in HIRc cells. Thus, insulin-mediated CREB phosphorylation appeared to be transcriptionally relevant.
CREB was initially characterized as a substrate of PKA. Activation of PKA by increases in intracellular cAMP results in the increase of CREB transcriptional transactivation activity through the phosphorylation of CREB serine 133 (22, 31). We have shown here that the treatment of hepatoma, fibroblast, and adipocyte cells with insulin also results in the phosphorylation of CREB at serine 133. The importance of CREB serine 133 phosphorylation following insulin treatment was further highlighted by experiments in which mutation of serine 133 to alanine completely blocked the insulin responsiveness of a chimeric Gal4-CREB protein in transfection assays. Mutation of other individual CREB serine residues to alanines had no significant effect on insulin responsiveness. These observations were consistent with data from other groups regarding the commonality of serine 133 for CREB transcriptional regulation by cAMP, NGF, fibroblast growth factor, and calcium (21-24, 31, 37, 39, 42).
Interestingly, although insulin or Bt2cAMP alone stimulates CREB activity, the simultaneous addition of both agents produced only a minimal increase in CREB transcriptional activity in HepG2 and 3T3-L1 fibroblasts, rather than an additive or synergistic stimulation.3 This is consistent with the observations from other groups (33) wherein cAMP stimulation led to a refractory period for subsequent activation. This effect was thought to be mediated by a non-kinase-dependent binding of RSK kinase to CREB binding protein (CBP) and a subsequent disruption of CREB-CBP-induced transcription (40). Our data support the hypothesis that multiple signaling pathways leading to CREB phosphorylation and transcriptional activation may not be synergistic.
Deciphering the pathway activated by insulin responsible for CREB
phosphorylation and activation is important because the multiple
post-receptor pathways activated by insulin presented a number of
possibilities. The data presented in this paper strongly support the
role of Ras Raf-1
MEK
ERK1/2 kinase pathway which is
analogous to the observations of Ginty et al. (24) with NGF.
The relevance of CREB regulation by insulin is highlighted by our
demonstrating that activation of transcription from the PEPCK, FAS, and
FABP gene promoters is blocked by dominant negative CREB in adipocytes.
It will be interesting to define the phenotypic consequences of this
novel mechanism of insulin-modulated gene expression.
![]() |
ACKNOWLEDGEMENTS |
---|
We acknowledge Elizabeth Millard for technical assistance. We thank Boris Draznin for support and thoughtful review of the manuscript. We appreciate the excellent secretarial support of Gloria Smith.
![]() |
FOOTNOTES |
---|
* This research was supported by National Institutes of Health Grants GM47117 (to D. J. K.) and DK02351, Veterans Administration Merit and Career Development Awards (to J. E-B. R.), and a Canadian Diabetes Association grant (to W. J. R.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ Both authors contributed equally to this work.
§§ To whom correspondence should be addressed: Section of Endocrinology (111H), Veterans Affairs Medical Center, 1055 Clermont St., Denver, CO 80220. Tel.: 303-399-8020 (ext. 2775); Fax: 303-393-5271; E-mail: jreusch{at}sembilan.uchsc.edu.
1 The abbreviations used are: CRE, cAMP responsive elements; CREB, cAMP-response element binding protein; MAP, mitogen-activated protein; MEK, MAP kinase kinase; FAS, fatty-acid synthetase; FABP, fatty acid binding protein; NGF, nerve growth factor; PKA, protein kinase A; PEPCK, phosphoenolpyruvate carboxykinase; TK, thymidine kinase; FCS, fetal calf serum; DMEM, Dulbecco's modified Eagle's medium; Bt2cAMP, dibutyryl cyclic AMP; PVDF, polyvinylidene difluoride; Ab, antibody; KAP, kinase-activated protein.
2 D. J. Klemm, unpublished data.
3 J. E.-B. Reusch and D. J. Klemm, unpublished data.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|